<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias - Seeking Alpha</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta http-equiv="P3P" content='CP="IDC DSP COR ADM DEVi TAIi PSA PSD IVAi IVDi CONi HIS OUR IND CNT"' />

 <script type="text/javascript">
 window.qbaka || (function(a,c){a.__qbaka_eh=a.onerror;a.__qbaka_reports=[];a.onerror=function(){a.__qbaka_reports.push(arguments);if(a.__qbaka_eh)try{a.__qbaka_eh.apply(a,arguments)}catch(b){}};a.onerror.qbaka=1;a.qbaka={report:function(){a.__qbaka_reports.push([arguments, new Error()]);},customParams:{},set:function(a,b){qbaka.customParams[a]=b},exec:function(a){try{a()}catch(b){qbaka.reportException(b)}},reportException:function(){}};var b=c.createElement("script"),e=c.getElementsByTagName("script")[0],d=function(){e.parentNode.insertBefore(b,e)};b.type="text/javascript";b.async=!0;b.src="//cdn.qbaka.net/reporting.js";"[object Opera]"==a.opera?c.addEventListener("DOMContentLoaded",d):d();qbaka.key="697c30d6de0ec176f16bc61dacb2980d"})(window,document);qbaka.options={autoStacktrace:1,trackEvents:1};
 </script>

<script type='text/javascript'>
try {
  window.external.msSiteModeCreateJumplist('SeekingAlpha - Read, Decide, Invest.');
  window.external.msSiteModeAddJumpListItem('Portfolio' ,
  'http://seekingalpha.com/account/portfolio?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Breaking News - Real-time stock market news updates' ,
  'http://seekingalpha.com/news/all?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Investment Ideas' ,
  'http://seekingalpha.com/dashboard/investing_ideas?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Income Investing, Retirement Investing and Dividend Stocks' ,
  'http://seekingalpha.com/dashboard/investing_income?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('ETFs & Portfolio Strategy' ,
  'http://seekingalpha.com/dashboard/etfs?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Macro View, Market Economy' ,
  'http://seekingalpha.com/dashboard/macro_view?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('My Email Alerts' ,
  'http://seekingalpha.com/account/email_preferences?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
} catch (ex) {
}
</script>
<meta name="application-name" content="Seeking Alpha - Read, Decide, Invest."/>
<meta name="msapplication-TileColor" content="#360000"/>
<meta name="msapplication-TileImage" content="http://static.cdn-seekingalpha.com/images/media_kit/71cdea92-2dc1-419d-8d62-f68b74c1eda8.png"/>
<meta name="msapplication-tooltip" content="Seeking Alpha - Read, Decide, Invest." />
<meta name="msapplication-starturl" content="http://seekingalpha.com?source=ie_task" />
<meta name="msapplication-task" content="name=Portfolio ;action-uri=http://seekingalpha.com/account/portfolio?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Breaking News - Real-time stock market news updates ;action-uri=http://seekingalpha.com/news/all?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Investment Ideas ;action-uri=http://seekingalpha.com/dashboard/investing_ideas?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Income Investing, Retirement Investing and Dividend Stocks ;action-uri=http://seekingalpha.com/dashboard/investing_income?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=ETFs & Portfolio Strategy ;action-uri=http://seekingalpha.com/dashboard/etfs?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Macro View, Market Economy ;action-uri=http://seekingalpha.com/dashboard/macro_view?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=My Email Alerts ;action-uri=http://seekingalpha.com/account/email_preferences?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<!-- End IE9 Settings -->

<meta property="fb:admins" content="100006791796236" />

<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@sa_popular">
<meta name="twitter:title" content="ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias">
<link rel="search" type="application/opensearchdescription+xml" href="/javascripts/seeking.xml" title="SeekingAlpha Search" />
<meta name="robots" content="noarchive" /><meta property="og:image" content="http://static.cdn-seekingalpha.com/uploads/2013/8/19/social_sa_logo.png" />

<link rel="canonical" href="http://seekingalpha.com/pr/8276791-ARIAD-Announces-Positive-Opinion-by-the-European-Medicines-Agency-on-the-Continued-Availability-of-Iclusig-in-Patients-with-Leukaemias" />
<script>
  window.PAGE_START_TS = new Date().getTime(); //will be put in mone
</script>

<link href="http://static.cdn-seekingalpha.com/stylesheets/performance_layout_packaged.css?1388942477" media="screen" rel="stylesheet" type="text/css" /><link href="http://static.cdn-seekingalpha.com/stylesheets/performance_layout_b_packaged.css?1388942477" media="screen" rel="stylesheet" type="text/css" /><link href="http://static1.cdn-seekingalpha.com/stylesheets/article_packaged.css?1388942477" media="screen" rel="stylesheet" type="text/css" />
<script type="text/javascript">var siteon = false; var atest = true; var acounter = 0;</script>
<script type="text/javascript" src="/javascripts/siteon.js"></script>

<script type="text/javascript">
  var users_on_site='2,815,229';
  var user_cookie={};

  function readCookie(name) {
    var cookie = document.cookie.match(new RegExp('(^|;)\\s*' + escape(name) + '=([^;\\s]*)'));
    return (cookie ? unescape(cookie[2]) : null);
  }

  function addToCookie(key,value) {
    var arr=user_cookie[key].split(',');
    arr.push(value);

    user_cookie[key]=arr.join(',');
  }
  if (document.location.protocol == "https:") {
    document.write('<scr'+'ipt src="/account/no_cookie_key"></scri'+'pt>');
  } else if (readCookie('user_cookie_key')) {
    document.write('<scr'+'ipt src="http://static.cdn-seekingalpha.com/account/cookie/'+readCookie('user_cookie_key')+'"></scri'+'pt>');
  } else if (readCookie('user_id')) {
    document.write('<scr'+'ipt src="http://seekingalpha.com/account/no_cookie_key"></scri'+'pt>');
  }
  
    (function(){
      var url='/pr/8276791-ARIAD-Announces-Positive-Opinion-by-the-European-Medicines-Agency-on-the-Continued-Availability-of-Iclusig-in-Patients-with-Leukaemias';
      if (location.pathname!=url){
        if (window.history && history.replaceState) history.replaceState("", "", url+location.search);
        else location.href=url+location.search;
      }
    })();

  var isThisMyFirstPV = false;
  var _comscore = _comscore || [];
  _comscore.push({ c1: "2", c2: "8500672" });
  (function() {
    var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
    s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
    el.parentNode.insertBefore(s, el);
  })();
  var _sf_startpt=(new Date()).getTime(); // chartbeat code
  var is_pro = false;
  if (document.location.protocol == "https:") {
    document.write('<link rel="shortcut icon" type="image/ico" href="https://seekingalpha-a.akamaihd.net/favicon.ico" />')
  } else {
    document.write('<link rel="shortcut icon" type="image/ico" href="http://static.cdn-seekingalpha.com/favicon.ico" />')
  }
  
    
  var ASSET_HOSTS = ["http://static.cdn-seekingalpha.com","http://static1.cdn-seekingalpha.com","http://static2.cdn-seekingalpha.com","http://static3.cdn-seekingalpha.com"];
</script>

<script src="http://static.cdn-seekingalpha.com/javascripts/common_packaged.js?1388942431" type="text/javascript"></script>
<script src="http://static.cdn-seekingalpha.com/javascripts/common2_packaged.js?1388942434" type="text/javascript"></script><script src="http://static3.cdn-seekingalpha.com/javascripts/common_article_packaged.js?1388942435" type="text/javascript"></script>
<script src="//partner.googleadservices.com/gampad/google_service.js" type="text/javascript"></script>
<script>
  if (SA.Data && SA.Data.Cache) {
    var adata = SA.Data.Cache.get('campaign_content');
  }
</script>

<script type="text/javascript">
  if ((user_email_cookie=readCookie('user_email')) && user_email_cookie.indexOf('@gmail.com')!=-1) {
    createCookie('user_email',(user_email_cookie.replace('@gmail.com','').replace(/\./gi,'').replace(/\+(.*?)$/,''))+'@gmail.com',365);
  }

  if (typeof(readCookie) == "function" && readCookie('user_vocation')) {
    createCookie('u_voc',readCookie('user_vocation'),3000);
  }
  if (readCookie('sapu') == "121") {eraseCookie('sapu');}
  var user_cookie = user_cookie || {};
  eraseCookie("__article_last_size");

if (top.location.pathname == "/" && readCookie('user_id')==957061) {
  var old_SADataCookies = SA.Data.Cookies.get;
  SA.Data.Cookies.get = function(x){if (x=="user_following_users" || x=="user_watchlist_authors") return ""; else return old_SADataCookies(x);}
}
  try{(function(){
    var uc=SA.Data.Cookies.get("user_cookie_key"), t=uc ? uc.match(/t=([0-9]+)/) : null;
    if (t && t[1] < 1367771521) SA.Data.Cookies.set("user_cookie_key","");
  })();} catch(e){}

</script>


<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-5.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"c0370b1d43","applicationID":"334927,334964","transactionName":"cldeEUAJWgldEBsASkVRUwlXFRkWUA1DPlZUT0M=","queueTime":0,"applicationTime":24,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-248.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),e[a].push(b),void 0)}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],"SvQ0B+":[function(a,b){function c(a){if(a===window)return 0;if(e.call(a,"__nr"))return a.__nr;try{return Object.defineProperty(a,"__nr",{value:d,writable:!1,configurable:!1,enumerable:!1}),d}catch(b){return a.__nr=d,d}finally{d+=1}}var d=1,e=Object.prototype.hasOwnProperty;b.exports=c},{}],id:[function(a,b){b.exports=a("SvQ0B+")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="http"+(a.sslForHttp?"s":"s"==l[4]?"s":"")+"://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>      <script type="text/javascript">
  var adblock = false;
  try{
    GS_googleAddAdSenseService("ca-pub-1420150919334552");
    GS_googleEnableAllServices();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense1","adsense down");
  }
</script>
<script type="text/javascript">
  try{
    GA_googleFetchAds();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense2","adsense down");
  }
</script>  </head>
    <body class="stretch_bg">
    <script>var ord = Math.floor(Math.random()*1000000000);</script>
<span class="seeking_alpha_site_title">Seeking Alpha</span>
<script type="text/javascript">
  if (readCookie('sa_mobile') == '1') {
    var aHTML =[];
    aHTML.push('<div class="mobile_or_full_site">');
      aHTML.push('<span class="mobile_site" onclick="eraseCookie(\'sa_mobile\');top.location.reload()">Click here to view mobile site</span>');
      aHTML.push('<div class="cleaner"></div>');
    aHTML.push('</div>');
    document.write(aHTML.join(""));
  }
</script>
<div class="promotion_cnt finance stars ipad_top">
  <div close="close"></div>
    <a onclick='Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_top_click");' href="/download-ipad-app?source=top_ipad_banner_large" class="promotion_video">
    <div class="ptext">
      <div class="ptext_t">Seeking Alpha Portfolio App for iPad</div>
      <div class="ptext_h">Finance</div>
      <div id='ipad_stars' class="stars stars_5"></div>
      <div class="rate">(<span class="rate_num" id="rate_num">1</span>)</div>
    </div>

    <div class="free"></div>
    <div class="sep"></div>
    <div class="ipad_screenshots"></div>
  </a>
</div>
<script>
  var ipadData;
  SeekingAlpha.Initializer.AddAfterLoad(function(){
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))){
      Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_displayed");
      ipadData = new SA.Data.iPad();
      ipadData.instanceName = "ipadData";
      var responseHandler = new Object();
      responseHandler.handleResponse = function(data){
        if (!data.averageUserRating) return;
        var stars = data.averageUserRating < 4 ? "4" : (data.averageUserRating+"").replace(".","");
        $("ipad_stars").className = "stars stars_"+stars;
        $("rate_num").innerHTML = data.userRatingCount;
      }
      ipadData.responseDelegate = responseHandler;
      ipadData.getData();
    }
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))) {
      $$("body")[0].addClassName('ipad_promotion')
    }
  });
</script>
<div id="header" class="not_logged_in header_nav">
  <div id="logo_and_navigation" class="logo_and_primary_navigation">
    <div id="comment_popup" style="position:relative; left:0; display:none">
  <div id="popup_secondary">
    <div id="inner_popup"></div>
  </div>
</div>    <span class="logo_old_h1"><a href="http://seekingalpha.com/" title="Seeking Alpha - Home Page" sasource="salogo"></a></span>
    
      <div class="item banner728x90" id='top_banner_728x90'>
          <script type="text/javascript">
            SA.Utils.Ads.add({el:$('top_banner_728x90'), HadCreated:false, size:'728x90', delta: null, NotSticky: true, info:'http://ad.doubleclick.net/adj/sek.breakingnews/news-article;sz=728x90;x=x;tile=1;d=breakingnews;t=news-article;t=article;'+dart_my_vocation_and_profiles()+'ord='+ord+'?', pos_key: '-vzt6gj4awf52'});
            SA.Utils.Ads.run();
          </script>
      </div>
    
  </div>
  <div class='nav_container_wrap' id='nav_container_wrap'>
  <div id="nav_container" headtab="">
    <div id="navi_cont">
      <ul id="navi" class="navi">
        <span id="old_dash">
          <li thistab='home' class="home">
            <a href="http://seekingalpha.com/" sasource="headtabs">Home</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='portfolio' class="portfolios">
            <a href="http://seekingalpha.com/account/portfolio" sasource="headtabs">Portfolio</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='market_news'>
            <a href="http://seekingalpha.com/news/all" sasource="headtabs">Breaking News</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='investing_ideas'>
            <a href="http://seekingalpha.com/analysis/investing-ideas/all" sasource="headtabs">Investing Ideas</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='investing_income'>
            <a href="http://seekingalpha.com/analysis/investing-income/all" sasource="headtabs">Dividends &amp; Income</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='etfs'>
            <a href="http://seekingalpha.com/analysis/etf-portfolio-strategy/all" sasource="headtabs">ETFs</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='macro_view'>
            <a href="http://seekingalpha.com/analysis/macro-view/all" sasource="headtabs">Macro View</a>
            <span class="navi_right_corner">|</span>
          </li>
        </span>
        
        <span id="new_dash" style="display:none">
          <li thistab='home' class="home">
            <a style="font-size:14px" href="http://seekingalpha.com/" sasource="headtabs">Home</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='portfolio' class="portfolios">
            <a style="font-size:14px" href="http://seekingalpha.com/account/portfolio" sasource="headtabs">My Portfolio</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='market_news'>
            <a style="font-size:14px" href="http://seekingalpha.com/news/all" sasource="headtabs">Breaking News</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='analysis'>
            <a style="font-size:14px" href="http://seekingalpha.com/analysis/all/most-popular" sasource="headtabs">Most Popular</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='alpha_rich'>
            <a style="font-size:14px" href="http://seekingalpha.com/dashboard/alpha-rich" sasource="headtabs">Top Ideas</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='stocktalks'>
            <a style="font-size:14px" href="http://seekingalpha.com/stocktalks/all" sasource="headtabs">StockTalk</a>
            <span class="navi_right_corner">|</span>
          </li>
        </span>

        <li thistab='alerts'>
          <a href="http://seekingalpha.com/real-time-alerts" sasource="headtabs">ALERTS</a>
            <span class="navi_right_corner">|</span>
          </li>
        <li thistab='pro' class="pro_tab">
            <a href="http://seekingalpha.com/account/pro" sasource="headtabs">PRO</a>
          </li>
        <li class="right_section">
          <div id="user_settings_wrapper"></div>
        </li>
      </ul>
    </div>
  </div>
</div>
<script>
  if ((!window.is_pro || SA.Data.User.id()==3) && ((window.user_cookie && window.user_cookie.stocktalker) || ABTest.identity%10==0)){
    $('old_dash').hide();
    $('new_dash').show();
  }
</script>

  <script type="text/javascript">
    SeekingAlpha.Initializer.LogAndRun(SA.Navigation.Top.init);
  </script>
</div>

<div id="main_container">
  <h1></h1>
  <div id="content_wrapper" class="article_pages">
    <img src="http://static.cdn-seekingalpha.com/images/universal/print_logo.png" width="48" height="20" id="print_seekingalpha_logo" />
    <div class="page_top">
      <div class="search_box_container_isolated">
  <div class="search_box">
    <form id="search_box_sa_search" method="get" class="linktosym comp search" action="/search/" onsubmit="return false;">
      <fieldset>
        <input id="autocomplete_sa_search" class="input_text text" type="text" value="search by symbol, author, keyword..." size="25" autocomplete="off" onblur="if($$('.search_box'))$$('.search_box')[0].style.background='';this.style.color=this.value=='' ? '#8D8D8D' : '#000000';handleInput(this,'blur')" onfocus="if($$('.search_box'))$$('.search_box')[0].style.background='#fff';this.style.color='#000000';handleInput(this,'focus')" afteruploadvalue='eFind quotes, people, expressions, transcripts' title='search by symbol, author, keyword...' class="find_transcripts" />
        <input type="button" class="search_button" value="" onclick="if ($('autocomplete_sa_search').value!=$('autocomplete_sa_search').title) AutoCompleteSAConfig.Packages.search.Find()" />
      </fieldset>
      <input type="hidden" name="source" value="search_general" />
      <input type="hidden" id="autocomplete_sa_hidden_search" name="q" value="" />
      <input type="hidden" name="cx" value="018269914407235029540:cdhc2yeo2ko" />
      <input type="hidden" name="cof" value="FORID:11;NB:1" />
      <input type="hidden" name="goto_search_tab" value="" />
    </form>
    <script type="text/javascript">SeekingAlpha.Initializer.LogAndRun(function () { AutoCompleteSAConfig.Load('search', { Symbols:true, IframeCover:true, AfterInsert:function () { this.Find(); }, AfterSubmit:function () { this.Find(); }}) });</script>
    <script type="text/javascript" src="http://www.google.com/coop/cse/brand?form=searchbox_018269914407235029540%3Acdhc2yeo2ko&lang=en"></script>
  </div>
</div>
      <div id="page_header">
  <h1>ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias</h1>
  <div id="article_info">
    <div class="article_news_info_pos">
      
      <span id="page_position"></span>
      <span class="a_date">Fri November 22, 2013   7:46 AM</span>
        &nbsp;|&nbsp;About:
        <span id="about_stocks">
          <a href="/symbol/aria" title='ARIAD Pharmaceuticals, Inc.'>ARIA</a>
        </span>
    </div>
    &nbsp;&nbsp;&nbsp;
  </div>
</div>
    </div>
    <div class="cleaner"></div>
    <div id="main_content" class="no_big_gaps_main_content">
      <div id="secondary_ads" class="no_big_gaps_secondary_ads">
        <div class="news_provider">
          <div class="newp_title"><strong>NEWS</strong> PROVIDED BY:</div>
          <div class="newp_who">Business Wire</div>
        </div>
        <div class="stickyad_wrapper">
          <div class="item banner160x600" id="fixed_banner160x600">
            <script>add_js_to_ad_call('http://ad.doubleclick.net/adj/sek.breakingnews/news-article;sz=160x600;x=x;tile=3;d=breakingnews;t=news-article;t=article;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');</script>
          </div>
        </div>
      </div>
      <div id="article_body_container" class="no_big_gaps_article_body_container">
        <div id="article_body">
          <div>
<p>
      Recommendations made to minimize risk of occlusive vascular events
    </p>



    <p>    <span class="location">CAMBRIDGE, Mass.</span> &amp; LAUSANNE, <span class="location">Switzerland</span>--(BUSINESS WIRE)--
      <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ariad.com%2F&amp;esheet=50756558&amp;newsitemid=20131122005330&amp;lan=en-US&amp;anchor=ARIAD+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=5061c5facca425e2245c1d9472974187">
      <span class="org">ARIAD
      Pharmaceuticals, Inc.</span>
    </a> (NASDAQ:ARIA) today announced adoption of a
      positive opinion by the Committee for Human Medicinal Products (CHMP) of
      the <span class="org">European Medicines Agency</span> (EMA) on the continued availability of
      Iclusig<sup>®</sup> (ponatinib) in the EU for use in patients in its
      authorized indications. Following its review of updated clinical-trial
      data on Iclusig, the CHMP made a series of recommendations on measures
      to help minimize the risk of occlusive vascular events in patients
      taking Iclusig. The authorized indications of Iclusig, as approved in
      July 2013, are as follows:
    </p>
    <ul><li>
        The treatment of adult patients with chronic phase, accelerated phase
        or blast phase chronic myeloid leukaemia (CML) who are resistant to
        dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib
        and for whom subsequent treatment with imatinib is not clinically
        appropriate; or who have the T315I mutation, or
      </li>
      <li>
        The treatment of adult patients with <span class="location">Philadelphia</span>-chromosome positive
        acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to
        dasatinib; who are intolerant to dasatinib and for whom subsequent
        treatment with imatinib is not clinically appropriate; or who have the
        T315I mutation.
      </li>
    </ul><p>
      The EMA has recommended the following:
    </p>
    <ul><li>
        Iclusig should not be used in patients with a history of heart attack
        or stroke, unless the potential benefits of treatment outweigh the
        risks.
      </li>
      <li>
        The cardiovascular status of patients should be assessed and
        cardiovascular risk factors actively managed before starting treatment
        with Iclusig. Cardiovascular status should continue to be monitored
        and optimised during treatment.
      </li>
      <li>
        Hypertension should be controlled during treatment with Iclusig, and
        healthcare professionals should consider interrupting treatment if
        hypertension is not controlled.
      </li>
      <li>
        Patients should be monitored for evidence of vascular occlusion or
        thromboembolism, and treatment should be interrupted immediately if
        this occurs.
      </li>
    </ul><p>
      The EMA plans to conduct a further review of the benefits and risks of
      Iclusig and may make additional recommendations on how Iclusig should be
      used.
    </p>
    <p>
      We have been working closely with the EMA to provide updated
      clinical-trial data on patients treated with Iclusig, said Jonathan E.
      Dickinson, general manager, ARIAD Pharmaceuticals (<a href="http://seekingalpha.com/symbol/aria">ARIA</a>) (<span class="location">Europe</span>). The
      conclusions reached by the CHMP, which were announced today, confirm a
      positive benefit-risk assessment for Iclusig after considering the most
      recent safety information. We expect that this will provide helpful
      guidance for patients and healthcare professionals as they consider the
      treatment options.
    </p>
    <p>
      The CHMP is a scientific committee composed of representatives from the
      28-member states of the EU, and <span class="location">Iceland</span> and <span class="location">Norway</span>. The CHMP reviews
      medical product applications on their scientific and clinical merit and
      provides advice to the <span class="org">European Commission</span>, which has the authority to
      approve medicines for the EU.
    </p>
    <p>
      CML is a cancer of the white blood cells that is diagnosed in
      approximately 7,000 patients each year in <span class="location">Europe</span>
    <sup>[1]</sup>. CML and
      Ph+ ALL patients treated with tyrosine kinase inhibitors (TKIs) can
      develop resistance or intolerance over time to these therapies. Iclusig
      is a targeted cancer medicine discovered and developed at ARIAD. It was
      designed by ARIAD scientists using ARIADs platform of computational
      chemistry and structure-based drug design to inhibit BCR-ABL, including
      drug-resistant mutants that arise during treatment. Iclusig is the only
      TKI that has been approved/received a marketing authorisation for an
      indication that includes CML and Ph+ ALL patients with the T315I
      mutation.
    </p>
    <p>
      About CML and Ph+ ALL
    </p>
    <p>
      <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ariad.com%2Fwt%2Ftertiarypage%2FAP24534_CML&amp;esheet=50756558&amp;newsitemid=20131122005330&amp;lan=en-US&amp;anchor=CML&amp;index=2&amp;md5=b218beb4b041d01a2b7f58df5cb758a2">CML</a>
      is characterized by an excessive and unregulated production of white
      blood cells by the bone marrow due to a genetic abnormality that
      produces the BCR-ABL protein. After a chronic phase of production of too
      many white blood cells, CML typically evolves to the more aggressive
      phases referred to as accelerated phase and blast crisis. Ph+ ALL is a
      subtype of acute lymphoblastic leukaemia that carries the Ph+ chromosome
      that produces BCR-ABL. It has a more aggressive course than CML and is
      often treated with a combination of chemotherapy and tyrosine kinase
      inhibitors. The BCR-ABL protein is expressed in both of these diseases.
    </p>
    <p>
      About ARIAD
    </p>
    <p>
      ARIAD Pharmaceuticals, Inc., headquartered in <span class="location">Cambridge, Massachusetts</span>
      and <span class="location">Lausanne</span>, <span class="location">Switzerland</span>, is an integrated global oncology company
      focused on transforming the lives of cancer patients with breakthrough
      medicines. ARIAD is working on new medicines to advance the treatment of
      various forms of chronic and acute leukemia, lung cancer and other
      difficult-to-treat cancers. ARIAD utilizes computational and structural
      approaches to design small-molecule drugs that overcome resistance to
      existing cancer medicines. For additional information, visit <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ariad.com%2F&amp;esheet=50756558&amp;newsitemid=20131122005330&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.ariad.com&amp;index=3&amp;md5=544af18e4531e35b8d08e9060ff90f63">http://www.ariad.com</a> or
      follow ARIAD on Twitter (<a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fariadpharm&amp;esheet=50756558&amp;newsitemid=20131122005330&amp;lan=en-US&amp;anchor=%40ARIADPharm&amp;index=4&amp;md5=1bd12ee815ffccc407eaae2d1bed20d5">@ARIADPharm</a>).
    </p>
    <p>
      This press release contains forward-looking statements including, but
      not limited to, updates on regulatory developments in <span class="location">Europe</span>.
      Forward-looking statements are based on management's expectations and
      are subject to certain factors, risks and uncertainties that may cause
      actual results, outcome of events, timing and performance to differ
      materially from those expressed or implied by such statements. These
      risks and uncertainties include, but are not limited to, a decision by
      the <span class="org">European Commission</span> not to adopt the recommendation of the CHMP or
      to adopt the recommendation but with revisions affecting the Companys
      ability to successfully launch, commercialize and generate profits from
      sales of Iclusig; the impact of the strengthened warnings recommended by
      the CHMP on sales of Iclusig; difficulties in commercializing Iclusig
      arising from the post-marketing approval review process or from its
      results; the emergence of other safety concerns based on additional
      adverse events in patients being treated with Iclusig and other risk
      factors detailed in the Company's public filings with the <span class="org">U.S.
      Securities and Exchange Commission</span>. The information contained in this
      press release is believed to be current as of the date of original
      issue. The Company does not intend to update any of the forward-looking
      statements after the date of this document to conform these statements
      to actual results or to changes in the Company's expectations, except as
      required by law.
    </p>
    <p>
      Reference:
    </p>
    <p>
      1. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia
      (CML). <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F19959081%3Fdopt%3DAbstract%26reason%3D0&amp;esheet=50756558&amp;newsitemid=20131122005330&amp;lan=en-US&amp;anchor=Best+Pract+Res+Clin+Haematol&amp;index=5&amp;md5=d61baadb391cc8328328e95093160085">Best
      Pract Res Clin Haematol</a>. 2009 Sep;22(3):295-302. Based on current
      estimate of population of <span class="location">Europe</span> (738,199,000 in 2010).
    </p>
    <p>
    </p>
  <p>
    <img src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20131122005330r1&amp;sid=acqr7&amp;distro=nx" alt="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20131122005330r1&amp;sid=acqr7&amp;distro=nx"/></p>



    <p>
      ARIAD Pharmaceuticals, Inc.
    <br/>For Investors<br/>Kendra
      Adams, 617-503-7028<br/>Kendra.adams@ariad.com
    <br/>or<br/>For
      U.S. Media<br/>Liza Heapes, 617-621-2315<br/>liza.heapes@ariad.com
    <br/>or<br/>For
      EU Media<br/>Heather Grant, +44 (0) 207 632 1873<br/>hgrant@biosector2.co.uk
    </p>


<p>Source: ARIAD Pharmaceuticals, Inc.
  </p>
Copyright Business Wire 2013</div>                  </div>
        <div class="cleaner"></div>
        <div id="content_follow_up">
          <div class="share_this_page_article_bottom">
            <ul id="page_toolbar" class="page_toolbar">
  <li class="share_this_page_article_toolbar">
    <div class="share_this_page_snippet">
  <div id="first_line_info" style="width:490px">
    <div class="left"><h6><span id="share_slogan" class="fs16">Share this press release with a colleague</span></h6></div>
  </div>
  <div class="widgets">
    <!-- Email -->

      <span class="email_this" onclick="email_story_to_friends('AcquireStory',8276791,'http://seekingalpha.com/pr/8276791-ARIAD-Announces-Positive-Opinion-by-the-European-Medicines-Agency-on-the-Continued-Availability-of-Iclusig-in-Patients-with-Leukaemias')">
        <div class="email_button"></div>
        <div class="email_bubble">
          <span id="widget_email_count"></span>
          <span class="cor_right"></span>
        </div>
      </span>
    <!-- twitter -->
    <span class="twitter_small">
        <a href="https://twitter.com/share" class="twitter-share-button twitter_share" data-via="salphatrending" data-related="salphatrending" data-count="horizontal">Tweet</a>
    </span>
    <!-- Linked In -->
      <span id="linkedin_1" class="linkedin_small linkedin_share"><script type="IN/Share" data-counter="right" data-onsuccess="linkedin_callback"></script></span>
    <!-- facebook -->
    <span id="span_fb_widget_like" class="facebook_small facebook_share"><div class="fb-like" data-href="http://seekingalpha.com/pr/8276791-ARIAD-Announces-Positive-Opinion-by-the-European-Medicines-Agency-on-the-Continued-Availability-of-Iclusig-in-Patients-with-Leukaemias?source=facebook" data-send="false" data-layout="button_count" data-show-faces="false" data-font="tahoma"></div></span>
    <div onclick="alert('click')">
      <div id="span_fb_widget_share" style="display: none; background: ur('/images/facebook_small.gif');" class="fb-share-button fl ml-10 mt1" data-href="http://seekingalpha.com/pr/8276791-ARIAD-Announces-Positive-Opinion-by-the-European-Medicines-Agency-on-the-Continued-Availability-of-Iclusig-in-Patients-with-Leukaemias?source=fb_share" data-type="button_count"></div>
    </div>
    <!-- Plusone  -->
      <span id="pluszone" class="plusone_wrap"><span class="plusone plusone_share"><div class="g-plusone" data-size="medium" annotation="bubble" data-width="65" data-callback="plusone_callback"></div></span></span>
    <!-- print -->
      <span class="print_this" onclick="print_article('with_comments')"><Print><div class="print_button"></div></span>
  </div>
</div>

  <script>
     //FB Share button test
     $('span_fb_widget_like').hide();
     $('span_fb_widget_share').show();
     setTimeout(function(){$('span_fb_widget_share').style.background="none";}, 15000);
     $('pluszone').setStyle({'margin-left':'5px'});


    SeekingAlpha.Initializer.AddAfterLoad(function(){
      new Ajax.Updater({success: 'widget_email_count'}, '/form/ajax_get_email_count', {
        method: 'get',
        parameters: {
          item_name: 'AcquireStory',
          article_id: '8276791'
        }
      });
    });

  </script>









  </script>
  </li>
</ul>          </div>
          <div class="cleaner"></div>
          <div class="follow_up_related">
              <h4 class="follow_up_related_title">More Articles You May Like</h4>
  <ul class="follow_up_related_ul" id="article_related_articles">
      <li id="article_related_articles_1911851" class="follow_up_related_li">
        <a onclick="Mobile_GA.sendEvent({label:'More Articles You May Like 1'})" href="/article/1911851-These-Small-Cap-BioPharma-Companies-Have-Catalysts-Upcoming" sasource="article_lb_author_1">These Small-Cap BioPharma Companies Have Catalysts Upcoming</a>
      </li>
      <li id="article_related_articles_1912401" class="follow_up_related_li">
        <a onclick="Mobile_GA.sendEvent({label:'More Articles You May Like 2'})" href="/article/1912401-Dont-Buy-Ariad-Pharmaceuticals-Shares-At-These-Levels" sasource="article_lb_author_2">Don&#x27;t Buy Ariad Pharmaceuticals Shares At These Levels</a>
      </li>
      <li id="article_related_articles_1906261" class="follow_up_related_li">
        <a onclick="Mobile_GA.sendEvent({label:'More Articles You May Like 3'})" href="/article/1906261-Following-Smart-Money-Baker-Brothers-LLC-Investments-In-2013-And-Beyond" sasource="article_lb_author_3">Following Smart Money: Baker Brothers LLC Investments In 2013 And...</a>
      </li>
      <li id="article_related_articles_1904651" class="follow_up_related_li">
        <a onclick="Mobile_GA.sendEvent({label:'More Articles You May Like 4'})" href="/article/1904651-Ariad-Pharmaceuticals-Positive-News" sasource="article_lb_author_4">Ariad Pharmaceuticals - Positive News</a>
      </li>
  </ul>
  <script>remove_current_article_related_articles()</script>
              <div class="follow_up_related_line">
              <span class="follow_up_related_title">Related stocks: </span>
                <a href="/symbol/aria" title='ARIAD Pharmaceuticals, Inc.' sasource="article_lb_stocks">ARIA</a>              </div>
          </div>
          <div class="comments_with_more">
            <div id='comments'><a name="comments_header" id="comments_header"></a>


<div id="notice_wrapper_comments_list" class="notice_message"><span id="notice_comments_list"></span></div><script type='text/javascript'>SeekingAlpha.Initializer.LogAndRun(function () { notice_to_element("comments_list","update"); })</script>
<ul id="talkback_list">
</ul>
<div id="continue_load_comments" class="continue_load_comments_button" style="display:none;" onclick="continue_loading_comments();">
	<div class="l"></div>
  <div class="c">Load All Comments</div>
  <div class="r"></div>
</div>
<div id="comment_form_wrapper">
  
  <div id="comment_form_AcquireStory_8276791">

  <script>
    reply_to_comment('AcquireStory_8276791',"")
  </script>

  </div>

  <script type="text/javascript">
    function getSpellCheckArray() {
      return [[document,"comment_form_txtar"]];
    }
    SeekingAlpha.Initializer.AddAfterLoad(function () { jspellInit(); });
  </script>

  <div class='cleaner'></div></div>
</div>

<script>mark_new_comments_if_tracking_source();</script>          </div>
          <br class="cleaner" />
        </div>
      </div>
    </div>
      <script>var page_ad_src = 'http://ad.doubleclick.net/adj/sek.breakingnews/news-article;sz=300x251;x=x;tile=4;d=breakingnews;pos=b;t=news-article;t=article;'+dart_my_vocation_and_profiles()+'ord='+ord+'?';</script>
  <div id="ads_and_tools" class="article_sidebar_tools red_sidebar">
      <div class="item banner300x600">
        <script>add_js_to_ad_call('http://ad.doubleclick.net/adj/sek.breakingnews/news-article;sz=300x250,300x600;x=x;tile=2;d=breakingnews;pos=t;t=news-article;t=article;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');</script>
      </div>
        

      

        <div id="article_sidebar" class="article_sidebar">
          <div id="sidebar_down"><img src="http://static.cdn-seekingalpha.com/images/loader_recommended_articles.gif" width="64" height="64" class="loader"/></div>
        </div>

        <div class="cleaner"></div>
        <div class="stickyad_wrapper">
          <div class="item banner300x250" id="article_dart_sticky"></div>
        </div>
      <script>
          SA.Utils.Ads.add({el:$('article_dart_sticky'), HadCreated:false, size:'300x250', delta:50, info:'http://ad.doubleclick.net/adj/sek.breakingnews/news-article;sz=300x251;x=x;tile=4;d=breakingnews;pos=b;t=news-article;t=article;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
      </script>
  </div>
  </div>
</div>
<div id='footer_break'><div></div></div><div id="footer">
  <div id="footernav">
    <div class="footernav_left">
      <a href="http://seekingalpha.com" class="footernav_logo"></a>
      <div class="footernav_boards">
        <div><span class="footer_title">TOP AUTHORS:</span>&nbsp;<a class="top_authors" href="http://seekingalpha.com/leader-board/opinion-leaders">The Opinion Leaders</a></div>
        <div class='top_boards'>
          <span class="footer_title">TOP USERS:</span>
          <a href="http://seekingalpha.com/leader-board/top-stocktalkers">StockTalkers</a> <span class="fl_dash">|</span>
          <a href="http://seekingalpha.com/leader-board/top-instablogs">Instablogs</a>
        </div>    
      </div>
      <div class="cleaner"></div>
    </div>
    
     <div class="footernav_share_buttons">
       <div class="fl">
         <div class="fb-like" data-href="http://www.facebook.com/pages/Seeking-Alpha/224867310939090" data-layout="button_count" data-show-faces="false" data-font="verdana" data-width="450">Follow us</div>
       </div>
      <div class="twitter_wrap ml0 fl"><a href="https://twitter.com/SAlphaTrending" class="twitter-follow-button twitter_share" data-show-count="false">Follow us</a></div>
    </div>
    <div class="footernav_right">
      <div class="footernav_links">
        <a href="http://seekingalpha.com/apps" sasource="footer">Mobile Apps</a>&nbsp;&nbsp;|&nbsp;
        <a class="small_rss" href="http://seekingalpha.com/page/feeds" sasource="footer">&nbsp;&nbsp;&nbsp;&nbsp;RSS Feeds</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/about_us" sasource="footer">About Us</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/contact" sasource="footer">Contact Us</a>
      </div>
      <div class="footernav_more_links">
        <a href="http://seekingalpha.com/page/terms-of-use" sasource="footer">Terms of Use</a> |
        <a href="http://seekingalpha.com/page/privacy" sasource="footer">Privacy</a> |
        <a href="http://www.xignite.com" rel="nofollow" target="_blank">Xignite quote data</a> |
        <span>&#169; 2014 Seeking Alpha</span>
      </div>
      <div class="cleaner"></div>
    </div>
  </div>
  <div class="cleaner"></div>
</div><script>SA.Pages.Article.getRelatedSidebar();</script>
    <script src="http://static2.cdn-seekingalpha.com/javascripts/jspell_packaged.js?1388942448" type="text/javascript"></script>
<link href="http://static3.cdn-seekingalpha.com/stylesheets/footer_packaged.css?1388942478" media="screen" rel="stylesheet" type="text/css" /><script type="text/javascript">
  if(typeof (authors) == "undefined" || typeof (symbols) == "undefined")
    load_remote_script("http://static2.cdn-seekingalpha.com/javascripts/sa.js?1388942417");
  if(is_users_cookie_exists() && !cookieExists('tops') && typeof(tops) == "undefined")
    load_remote_script("http://static3.cdn-seekingalpha.com/javascripts/tops.js?1388942166");
  Mone.renderedParams = {};
  SeekingAlpha.Initializer.AddAfterLoad(function(){SA.Performance.Utils.loadPrintStyle('http://static1.cdn-seekingalpha.com/stylesheets/print.css?t=1388942550')});

  if (SA && SA.Data && SA.Data.User && SA.Data.User.loggedIn() && SA.Data.User.email() && SA.Data.User.email().match(/@seekingalpha.com/)){
    try{$('user_settings_pop').children[0].insert("<li class='mt10'><a href='javascript:void(0)' onclick='switch_status()'>PRO ON / OFF</a></li>");}catch(e){}
  }

  function switch_status(){
    new Ajax.Request('/authentication/get_menu', {
      asynchronous:true,
      method:'get',
      onComplete: function(transport) {
        eval(transport.responseJSON.code);
      }
    });
  }

  try{
    if (!siteon) {
      $('header').outerHTML += '<div id="outage_message">Most of Seeking Alpha is currently unavailable due to scheduled maintenance. Most published articles are still available for viewing. We apologize for any inconvenience.</div>';
      $('user_settings_wrapper').hide();
      $('outage_message').style.top = document.viewport.getDimensions().height -48 + "px";
    }
  } catch(e){}
</script>
<noscript>
  <img src="http://b.scorecardresearch.com/p?c1=2&c2=8500672&cv=2.0&cj=1" width="0" height="0" />
</noscript>
<script src="http://static.cdn-seekingalpha.com/javascripts/footer_packaged.js?1388942445" type="text/javascript"></script><div id="symbol_data_script_container"></div>
<script type="text/javascript">
SeekingAlpha.Initializer.onDOMLoad(function(){
  if(SA.Pages && SA.Pages.Account && SA.Pages.Account.Portfolios){
    var a = SA.Pages.Account.Portfolios.alertsTab;
    SA.Pages.Account.Portfolios.alertsTab = function(b){if ($('ziignight_submit')) a(b);}
if (getURLParam("pu")=="all_holdings") $("tab_"+Portfolio.current_tab).click();  
}
});
if (/\/account\/portfolio/.test(location.href)) {document.getElementsByTagName("html")[0].style.overflow = "auto"};
if (!$("comment_form_wrapper") && /seekingalpha\.com\/currents\/post/.test(location.href) && $("ads_and_tools")){ $("ads_and_tools").style.position = 'absolute';$("ads_and_tools").style.top="60px";$("ads_and_tools").style.right="0";};
</script>
<style>
.portfolio_news #content_wrapper .left_content .market_currents ul#mc_news li  .bullet{* position: static;* padding:0 6px 6px 1px;}
</style>
<script>
var pubnub_test = '$|892165|19770181|17136652|12809951|52832|234601|946066|138138|119840|158117|3|6383|531163|9393711|4726401|1107427|2120371|2632411|14916642|13142282|';
try{
var auth = "|" + SA.Data.Cookies.get('user_id') + "|";
if (pubnub_test.indexOf(auth) > 0) {
var scriptElement_n = document.createElement("script");
scriptElement_n.defer = "defer";
scriptElement_n.src = 'http://static.cdn-seekingalpha.com/javascripts/utils/sa_notify.js?149';
document.getElementsByTagName("head")[0].appendChild(scriptElement_n)
var scriptElement_n = document.createElement("script");
scriptElement_n.defer = "defer";
scriptElement_n.src = 'http://static.cdn-seekingalpha.com/javascripts/utils/notify.js?153';
document.getElementsByTagName("head")[0].appendChild(scriptElement_n);
var scriptElement = document.createElement("script");
scriptElement.defer = "defer";
scriptElement.src = 'http://static.cdn-seekingalpha.com/javascripts/chat.js?149';
document.getElementsByTagName("head")[0].appendChild(scriptElement);
var fileref=document.createElement("link")
fileref.setAttribute("rel", "stylesheet")
fileref.setAttribute("type", "text/css")
fileref.setAttribute("href", "http://static.cdn-seekingalpha.com/stylesheets/chat.css?147")
document.getElementsByTagName("head")[0].appendChild(fileref)
}
} catch(e) {
}
</script>



<script type="text/javascript">
  var _memb_status, _ticker, _pv_count, _user_agent;
  if (SA.Data && SA.Data.User && SA.Data.User.loggedIn())
  {
    _memb_status = SA.Data.User.hasRTA() ? SA.Data.User.hasanApp() ? "reg_yes_email_yes_app" : "reg_yes_email_no_app" : SA.Data.User.hasanApp() ? "reg_no_email_yes_app" : "reg_no_email_no_app";
    _pv_count = "reg_already";
  } else {
    _memb_status = "non_reg";
    _pv_count = readCookie("pages_viewed");
    if(_pv_count){
      var pv_int = parseInt(_pv_count);
      if(_pv_count >= 1 && _pv_count <= 2) _pv_count = "no_reg_2_to_3";
      else if(_pv_count >= 3 && _pv_count <= 8) _pv_count = "no_reg_4_to_9";
      else if(_pv_count >= 9 && _pv_count <= 61) _pv_count = "no_reg_10_to_62";
      else if(_pv_count >= 62 && _pv_count <= 143) _pv_count = "no_reg_63_to_144";
      else _pv_count = "no_reg_144_plus";
    } else {
        _pv_count = "no_reg_1";
    }
  }
  var _selector = $('about_primary_stocks');
  _ticker = _selector ? _selector.select('a')[0].innerText : "no_ticker";
  if (SA.Utils && SA.Utils.Env && SA.Utils.Env.isIPad) _user_agent = "ipad";
  else if(SA.Utils.Env.mobileOS) _user_agent = "mobile";
  else _user_agent = "desktop";
  var google_tag_params = {
    memb_status: _memb_status,
    tickers: _ticker,
    pv_count: _pv_count,
    user_agent: _user_agent
  };

  /* <![CDATA[ */
  var google_conversion_id = 976471699;
  var google_conversion_label = "yEDNCN3OkAoQk43P0QM";
  var google_custom_params = window.google_tag_params;
  var google_remarketing_only = true;
  /* ]]> */
</script>
<div style="display: none">
  <script type="text/javascript" src="//www.googleadservices.com/pagead/conversion.js">
  </script>
</div>
    <div class="cleaner"></div>
  </body>
</html>
